A number of other research firms have also weighed in on RGNX. Svb Leerink upgraded shares of Regenxbio from an underperform rating to a market perform rating and reduced their price objective for the company from $38.00 to $37.00 in a research note on Tuesday, August 20th. Zacks Investment Research raised shares of Regenxbio from a sell rating to a hold rating in a report on Thursday, July 25th. Morgan Stanley set a $84.00 price target on shares of Regenxbio and gave the company a buy rating in a report on Monday, July 15th. Evercore ISI set a $79.00 price target on shares of Regenxbio and gave the company a buy rating in a report on Wednesday, August 7th. Finally, Leerink Swann raised shares of Regenxbio from an underperform rating to a market perform rating in a report on Tuesday, August 20th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Regenxbio currently has a consensus rating of Buy and a consensus price target of $79.56.
Regenxbio stock opened at $37.92 on Thursday. Regenxbio has a 1-year low of $30.38 and a 1-year high of $83.45. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 15.93 and a beta of 0.82. The company has a current ratio of 14.58, a quick ratio of 14.58 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $38.06 and a 200 day simple moving average of $47.86.
In other Regenxbio news, SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total value of $264,950.00. Following the completion of the transaction, the senior vice president now directly owns 8,006 shares of the company’s stock, valued at approximately $424,237.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $37.55, for a total transaction of $563,250.00. Following the completion of the transaction, the insider now directly owns 261,000 shares of the company’s stock, valued at $9,800,550. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,000 shares of company stock valued at $2,608,800. Insiders own 13.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of RGNX. Korea Investment CORP bought a new stake in shares of Regenxbio during the 2nd quarter worth $20,675,000. UBS Group AG lifted its holdings in shares of Regenxbio by 438.6% during the 2nd quarter. UBS Group AG now owns 263,094 shares of the biotechnology company’s stock worth $13,515,000 after acquiring an additional 214,244 shares during the last quarter. Hillhouse Capital Advisors LTD. bought a new stake in shares of Regenxbio during the 2nd quarter worth $10,582,000. Nuveen Asset Management LLC bought a new stake in shares of Regenxbio during the 2nd quarter worth $10,206,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Regenxbio by 157.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 321,713 shares of the biotechnology company’s stock worth $13,496,000 after acquiring an additional 196,944 shares during the last quarter. 79.43% of the stock is owned by institutional investors.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: How to trade on quiet period expirations
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.